Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederbusinesswire.com
Business Wire Health: Clinical Trials News
Get the latest updates from Business Wire Health: Clinical Trials News directly as they happen.
Follow now 105 followers
Latest posts
Last updated 7 minutes ago
Tinnitus-Forschung: Wirkstoff AC102 lässt das Dauerpiepsen im präklinischen Modell verschwinden
7 minutes ago
ERLANGEN, Deutschland & BERLIN--(BUSINESS WIRE)--Der neue Wirkstoff AC102 konnte in einem präklinischen...
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
7 minutes ago
ERLANGEN, Germany & BERLIN--(BUSINESS WIRE)--The novel compound AC102 almost completely reversed tinnitus...
Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite
about 2 hours ago
STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a leading developer and supplier of critical raw materials...
ノボキュア、2025年ESMO消化器がん学会にて膵臓がんに対する腫瘍治療電場（TTフィールド）の第3相試験であるPANOVA-3試験の最終副次評価項目データを発表へ
about 4 hours ago
スイス、バール--(BUSINESS WIRE)--（ビジネスワイヤ） -- ノボキュア（NASDAQ：NVCR）は、切除不能な局所進行膵腺がんを対象とした腫瘍治療電場（TTフィールド）療法の第3相試験であるPANOVA-3試験における最終副次評価項目の結果を発表する予定であることを明らかにしました。これらのPANOVA-3のデータは、2025年7月2日から7月5日までスペイン・バルセロナで開催される欧州臨床腫瘍学会（ESMO）消化器がん学会において、速報演題として口頭発表に採択されました。 「PANOVA-3試験においてTTフィールドと化学療法を併用した患者は、化学療法単独の治療群と比較して、全生存期間における大幅な改善に加え、疼痛の進行およびオピオイド薬の使用開始の有意な遅延も示されました。膵臓がんは衰弱を伴う疼痛を引き起こすことで知られています。これらの症状を遅らせることは、患者の全体的な生活の質を維持することにつながります。本試験では、そのような有望な結果が確認されました」と、Vall d’Hebron大学病院の腫瘍内科医であり、Vall d’Hebron腫瘍研究所（VHIO
Novocure presenterà i dati finali dell’endpoint secondario dal trial di fase 3 PANOVA-3 sui Tumor Treating Fields (TTFields) nel carcinoma pancreatico al Congresso ESMO GI 2025
about 4 hours ago
BAAR, Svizzera--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ha annunciato oggi che presenterà i risultati...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
about 14 hours ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 14 hours ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 14 hours ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing...
Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development
about 16 hours ago
BOSTON--(BUSINESS WIRE)-- #ComputationalPathology--Modella AI enters into an agreement with AstraZeneca to access...
Alume Biosciences Announces Publication of Data Examining First-in-Human Use of Bevonescein to Illuminate Nerves in Nature Communications
about 17 hours ago
SAN DIEGO--(BUSINESS WIRE)--Alume Biosciences Announces Publication of Data Examining First-in-Human Use of...
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
about 19 hours ago
HYOGO, Japan--(BUSINESS WIRE)--JCR today announced that it achieved the enrollment of the...
Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treatment Options Worldwide
about 22 hours ago
CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--Asahi Kasei...